ICER plans to assess the comparative clinical effectiveness and value of idecabtagene vicleucel (Bristol-Myers Squibb, bluebird bio) and ciltacabtagene autoleucel (Johnson & Johnson, Legend Biotech Corp) for the treatment of multiple myeloma. An FDA decision on idecabtagene vicleucel is expected in early 2021. A BLA submission for ciltacabtagene autoleucel is expected by end of 2020.
Interventions of Interest:
- idecabtagene vicleucel (Abecma®, Bristol-Myers Squibb, bluebird bio)
- ciltacabtagene autoleucel (Johnson & Johnson, Legend Biotech Corp)
- Belantamab mafodotin (Blenrep™, GlaxoSmithKline)